Pfizer Inc. (PFE) Earnings
Pfizer Inc. is expected to report next earnings on August 4, 2026 (in NaN days), with a consensus EPS estimate of $0.68. PFE has beaten EPS estimates in 12 of its last 12 reported quarters (average surprise +24.0% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $0.72 | $0.75 | +3.9% | $14.5B | +4.4% |
| Feb 3, 2026 | $0.57 | $0.66 | +16.4% | $17.6B | +4.2% |
| Nov 4, 2025 | $0.63 | $0.87 | +37.4% | $16.7B | +0.9% |
| Apr 29, 2025 | $0.67 | $0.92 | +38.1% | $13.7B | -1.5% |
| Feb 4, 2025 | $0.47 | $0.63 | +33.6% | $17.8B | +2.4% |
| May 1, 2024 | $0.52 | $0.82 | +58.9% | $14.9B | +7.2% |
| Jan 30, 2024 | $-0.19 | $0.10 | +152.6% | $14.2B | +0.0% |
| Oct 31, 2023 | $-0.32 | $-0.17 | +46.9% | $13.2B | +4.0% |
| Aug 1, 2023 | $0.56 | $0.67 | +19.6% | $12.7B | +5.4% |
| May 2, 2023 | $0.98 | $1.23 | +25.5% | $18.3B | +10.2% |
| Jan 31, 2023 | $1.05 | $1.14 | +8.6% | $24.3B | -0.4% |
| Nov 1, 2022 | $1.39 | $1.78 | +28.1% | $22.6B | +7.4% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 5, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Good start to the year with business performing well. Made progress in delivering 2026 critical R&D milestones including positive phase three readouts. Strategic priorities include oncology, metabolic disease, vaccines. Macera acquisition underpins obesity therapy strategy. Nurtec shows power of leading field force and commercial capabilities. Embedding AI across company as key strategic priority.
Guidance
Reaffirms full year 2026 guidance with total company revenues expected in the range of $59.5 billion to $62.5 billion and adjusted diluted earnings per share in the range of $2.80 to $3 a share. Highlights sustained low disease levels of COVID will weigh on Paxlovid utilization and community sales occur towards end of year.
Segment performance
In the first quarter, launched and acquired products had a tremendous start with $3.1 billion in revenue and approximately 22% operational growth. Oncology's seeds and products saw 20% year-over-year operational revenue growth. Nurtec contributed with 41% operational growth in the first quarter driven by robust demand for acute and preventive migraine treatments.
Risks & headwinds
LOE headwinds over next few years, potential impact of vaccine market dynamics
Analyst Q&A
Q: And our first question today comes from Vommel Devon with Guggenheim. Curious about ABA meeting data and investor event details.
A: Detailed data from Vespa 3 will be shared, data from Vespa 1 open label extension and Vespa 2 will be shared, ADA data on amylin mono to be shared in second half;
Q: Next question from Dave Reisinger with Learing Partners on oncology readouts and corporate strategy restructuring.
A: Business development moved under Chris Bosso, commercial development into global marketing, Alexander took over portfolio management;
Q: Question from Chris Schott with J.P. Morgan on business trends and BD capacity.
A: Solid start in Q1, de-risked delivery without raising guidance, $7 billion BD capacity with focus on internal pipeline and potential larger transactions;
Q: Question from Carrie Holford with Barenburg on vaccination rates and European contracts.
A: Decline in Q1 community not related to vaccination, stable vaccination rates in Europe, discussed impact of Belgian court decision;
Q: Question from Uma Rafa with Evercore ISI on transformative M&A and dividend.
A: Open to M&A but not high priority now, Albert aims to continue tenure focusing on AI transformation and delivering value;
Q: Question from Asad Hader with Goldman Sachs on growth bridge and base business.
A: Base business trends predictable, LOE impact, pipeline risk adjusted driving growth from 2029;
Q: Question from Evan Zekerman with BMO Capital Markets on share repurchases.
A: Capital allocation focus on R&D and business development, share repurchase lever to come back;
Q: Question from Courtney Breen with Bernstein on sigvotartag-vidotin and phase three study.
A: Encouraged by data, phase three study recruiting, second-line study against dozitaxel, data to be shared;
Q: Question from Louise Chin with Scotia Bank on key products driving growth and international obesity.
A: Discussed echinoblutide launch in China, primary care and specialty care growth, assets in oncology and obesity driving growth